Research coauthored by RTI Health Solutions researchers will be presented at the 2022 Canadian Association for Population Therapeutics Conference.
Updated cost-utility and public health impact of recombinant zoster vaccine (RZV) in Canadians aged 50 years and older. George S, Carrico J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N.
Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D.
